AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors (NCT07094113)
A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combination with other agents in participants with advanced or metastatic solid tumors harboring KRAS alterations. This is a dose-escalation study in which participants will be assigned to multiple dose levels (DLs) of AMG 410, either as monotherapy or in combination with other agents, followed by expansion cohorts. The goal is to determine the Maximum Tolerated Dose (MTD)-the highest dose with acceptable safety and manageable side effects-or the Recommended Phase 2 Dose (RP2D) of AMG 410 in adult participants with KRAS-altered advanced or metastatic solid tumors.
Who can join: Review the eligibility criteria below.
Location: City of Hope National Medical Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (39 Sites)
Showing the first 25 of 39 sites.
- City of Hope National Medical Center — Duarte, California
- University of California Los Angeles — Los Angeles, California
- Emory University — Atlanta, Georgia
- Massachusetts General Hospital — Boston, Massachusetts
- Siteman Cancer Center - Washington University — St Louis, Missouri
- Duke Cancer Center — Durham, North Carolina
- Thomas Jefferson University — Philadelphia, Pennsylvania
- Sarah Cannon Research Institute Oncology Partners — Nashville, Tennessee
- Next Oncology — San Antonio, Texas
- Next Virginia — Fairfax, Virginia
- Chris OBrien Lifehouse — Camperdown, New South Wales
- The Queen Elizabeth Hospital — Woodville South, South Australia
- Peter MacCallum Cancer Centre — Melbourne, Victoria
- Universitair Ziekenhuis Antwerpen — Edegem,
- Universitair Ziekenhuis Gent — Ghent,
- Cross Cancer Institute — Edmonton, Alberta
- Princess Margaret Cancer Centre — Toronto, Ontario
- Sir Mortimer B Davis - Jewish General Hospital — Montreal, Quebec
- Beijing Cancer Hospital — Beijing, Beijing Municipality
- Chongqing University Cancer Hospital — Chongqing, Chongqing Municipality
- Jinan Central Hospital — Jinan, Shandong
- Rigshospitalet — Copenhagen,
- Centre Leon Berard — Lyon,
- Gustave Roussy — Villejuif,
- Universitaetsklinikum Essen — Essen,
📞 Contact the Study Coordinator
Phone: (866) 572-6436
Email: medinfo@amgen.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All KRAS Altered Advanced or Metastatic Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.